1.92
3.23%
0.06
After Hours:
1.95
0.03
+1.56%
Prokidney Corp stock is traded at $1.92, with a volume of 591.35K.
It is up +3.23% in the last 24 hours and down -20.00% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
See More
Previous Close:
$1.86
Open:
$1.86
24h Volume:
591.35K
Relative Volume:
0.85
Market Cap:
$241.39M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-3.5861
EPS:
-0.5354
Net Cash Flow:
$-124.27M
1W Performance:
-12.53%
1M Performance:
-20.00%
6M Performance:
+17.07%
1Y Performance:
-58.08%
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Prokidney Corp Stock (PROK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-21-22 | Initiated | Jefferies | Buy |
Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
Oct-18-22 | Initiated | UBS | Buy |
Oct-14-22 | Initiated | Citigroup | Buy |
Sep-23-22 | Initiated | BofA Securities | Buy |
Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
Recent Insider Activity Suggests Potential Gains for ProKidney Corp (PROK) - Knox Daily
ProKidney (NASDAQ:PROK) Coverage Initiated by Analysts at JPMorgan Chase & Co. - MarketBeat
An In-Depth Look at ProKidney Corp Inc. (PROK) Price Performance During Market Crashes - The InvestChronicle
ProKidney Corp (PROK)’s Day in Review: Closing at 1.86, Down by -8.82 - The Dwinnex
JPMorgan starts ProKidney stock coverage with Neutral rating - Investing.com
How does ProKidney Corp (PROK) change from a tortoise to a hare? - SETE News
Insider Selling: Weber Darin J., ProKidney Corp [PROK] Chief Regulatory Officer divested 16,412 shares - Knox Daily
Insiders Re-Evaluate Their US$54.7m Stock Purchase As ProKidney Falls To US$659m - Simply Wall St
ProKidney Corp (PROK) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Is it possible to buy ProKidney Corp(PROK) shares at a good price now? - US Post News
Examining the Potential Price Growth of ProKidney Corp (PROK) - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing ProKidney Corp (PROK)’s Performance - The Dwinnex
ProKidney revises Phase 3 program for lead asset - MSN
Reviewing LadRx (OTCMKTS:CYTR) and ProKidney (NASDAQ:PROK) - Defense World
ProKidney (NASDAQ:PROK) Sees Unusually-High Trading Volume - Defense World
ProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 16,412 Shares - MarketBeat
ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com South Africa
ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com Australia
ProKidney executive sells $41,030 in company stock - Investing.com India
ProKidney executive sells $41,030 in company stock - Investing.com
ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com UK
ProKidney (NASDAQ:PROK) Shares Down 6.7% - MarketBeat
Propel Hits 52-Week High on KOHO Link - Baystreet.ca
Propel Holdings Inc. - Baystreet.ca
Wall Street Analyst Initiated ProKidney Corp [PROK]. What else is Wall St. saying - The DBT News
ProKidney Corp [PROK] stock for 2,065 USD was sold by Weber Darin J. - Knox Daily
ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - MarketBeat
PROK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Stocks to Watch: Steelcase, Progyny, America's Car-Mart, Exicure - MarketWatch
ProKidney Corp (PROK) stock analysis: A simple moving average approach - US Post News
Potential Price Increase for ProKidney Corp (PROK) After Recent Insider Activity - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: ProKidney Corp (PROK) - SETE News
Financial Metrics Exploration: Understanding ProKidney Corp (PROK) Through Ratios - The Dwinnex
ProKidney (NASDAQ:PROK) Shares Gap Down to $2.38 - MarketBeat
ProKidney - The Pharma Letter
ProKidney (NASDAQ:PROK) Shares Down 3.3% - MarketBeat
ProKidney (NASDAQ:PROK) Now Covered by Analysts at Guggenheim - Defense World
Investing in ProKidney Corp (PROK) Is Getting More Attractive - Knox Daily
ProKidney (NASDAQ:PROK) Shares Gap Up to $2.39 - MarketBeat
ProKidney (NASDAQ:PROK) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Guggenheim highlights ProKidney stock upside in addressing unmet needs for CKD patients - Investing.com Canada
Guggenheim Initiates Coverage of ProKidney (PROK) with Buy Recommendation - Nasdaq
Guggenheim highlights ProKidney stock upside in addressing unmet needs for CKD patients - Investing.com
ProKidney updates on rilparencel’s registrational path to potential US approval - The Pharma Letter
ProKidney (NASDAQ:PROK) Trading 6% Higher - MarketBeat
ProKidney Suspends One of Its Two Phase 3 Kidney Cell Therapy Trials - DocWire News
ProKidney (NASDAQ:PROK) Price Target Lowered to $3.00 at Bank of America - Defense World
ProKidney (NASDAQ:PROK) Shares Gap Down on Analyst Downgrade - Defense World
ProKidney drops Phase III CKD study to focus on US market and save up to $175m - Clinical Trials Arena
BofA cuts ProKidney shares target as cash shortfall raises risksBofA - Investing.com
ProKidney drops Phase III CKD study to focus on US market and save up to $175m - Yahoo Finance
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):